Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Inventory (2023 - 2025)

Beta Bionics (BBNX) has disclosed Inventory for 3 consecutive years, with $21.7 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 63.08% to $21.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.7 million through Dec 2025, up 63.08% year-over-year, with the annual reading at $21.7 million for FY2025, 63.08% up from the prior year.
  • Inventory hit $21.7 million in Q4 2025 for Beta Bionics, up from $20.4 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $21.7 million in Q4 2025 to a low of $1.2 million in Q4 2023.
  • Historically, Inventory has averaged $15.0 million across 3 years, with a median of $16.5 million in 2025.
  • Biggest five-year swings in Inventory: skyrocketed 969.88% in 2024 and later soared 63.08% in 2025.
  • Year by year, Inventory stood at $1.2 million in 2023, then surged by 969.88% to $13.3 million in 2024, then skyrocketed by 63.08% to $21.7 million in 2025.
  • Business Quant data shows Inventory for BBNX at $21.7 million in Q4 2025, $20.4 million in Q3 2025, and $17.3 million in Q2 2025.